ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Abstract Background In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the “gold” standard therapy, up to 50% of patients relapse, needing radical cystectomy. Hence, alternative therapeutic strategies have been developed...

Full description

Bibliographic Details
Main Authors: Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, Emilio Sacco, Pier Francesco Bassi
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Cancer
Subjects:
EMDA
Device-assisted therapy
High risk non muscle-invasive bladder cancer
BCG failure
Mitomycin C
Salvage therapy
Online Access:http://link.springer.com/article/10.1186/s12885-018-5134-7

Internet

http://link.springer.com/article/10.1186/s12885-018-5134-7

Similar Items